EA202192900A1 - Модуляторы пути интегрированной реакции на стресс - Google Patents

Модуляторы пути интегрированной реакции на стресс

Info

Publication number
EA202192900A1
EA202192900A1 EA202192900A EA202192900A EA202192900A1 EA 202192900 A1 EA202192900 A1 EA 202192900A1 EA 202192900 A EA202192900 A EA 202192900A EA 202192900 A EA202192900 A EA 202192900A EA 202192900 A1 EA202192900 A1 EA 202192900A1
Authority
EA
Eurasian Patent Office
Prior art keywords
stress response
modulators
integrated stress
response pathways
compounds
Prior art date
Application number
EA202192900A
Other languages
English (en)
Inventor
Кристофер Джон Браун
Ирена Доли Ребуль
Йорк Рудхард
Мохамад Саббах
Дэрил Саймон Уолтер
Original Assignee
Эвотек Интернешнл Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эвотек Интернешнл Гмбх filed Critical Эвотек Интернешнл Гмбх
Publication of EA202192900A1 publication Critical patent/EA202192900A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы (I)или их фармацевтически приемлемым солям, сольватам, гидратам, таутомерам или стереоизомерам, где заместители с R1 по R3, A1 и A2 имеют значения, указанные в описании и пунктах формулы изобретения. Изобретение, кроме того, относится к фармацевтическим композициям, содержащим указанные соединения, их применению в качестве лекарственного препарата и в способе лечения и предотвращения одного или нескольких заболеваний или расстройств, связанных с интегрированной реакцией на стресс.
EA202192900A 2019-04-23 2020-04-22 Модуляторы пути интегрированной реакции на стресс EA202192900A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19170502 2019-04-23
PCT/EP2020/061148 WO2020216764A1 (en) 2019-04-23 2020-04-22 Modulators of the integrated stress response pathway

Publications (1)

Publication Number Publication Date
EA202192900A1 true EA202192900A1 (ru) 2022-03-18

Family

ID=66248567

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192900A EA202192900A1 (ru) 2019-04-23 2020-04-22 Модуляторы пути интегрированной реакции на стресс

Country Status (12)

Country Link
US (1) US20220213078A1 (ru)
EP (1) EP3959210A1 (ru)
JP (1) JP2022530051A (ru)
CN (1) CN114008041A (ru)
AU (1) AU2020262153A1 (ru)
BR (1) BR112021020106A2 (ru)
CA (1) CA3137212A1 (ru)
EA (1) EA202192900A1 (ru)
IL (1) IL287378A (ru)
MX (1) MX2021012904A (ru)
SG (1) SG11202111362SA (ru)
WO (1) WO2020216764A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006115A (es) 2017-12-13 2020-11-09 Praxis Biotech LLC Inhibidores de la vía de respuesta al estrés integrada.
KR20210021519A (ko) 2018-06-05 2021-02-26 프락시스 바이오테크 엘엘씨 통합 스트레스 반응 경로의 저해제
US11318133B2 (en) 2019-06-12 2022-05-03 Praxis Biotech LLC Modulators of integrated stress response pathway
AU2021236284A1 (en) 2020-03-11 2022-08-18 Evotec International Gmbh Modulators of the integrated stress response pathway
CN117098753A (zh) 2020-10-22 2023-11-21 埃沃特克国际有限责任公司 整合应激反应途径的调节剂
JP2023546225A (ja) 2020-10-22 2023-11-01 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 統合ストレス応答経路のモジュレーター
WO2022084447A1 (en) 2020-10-22 2022-04-28 Evotec International Gmbh Modulators of the integrated stress response pathway
WO2024109736A1 (zh) * 2022-11-21 2024-05-30 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其合成方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022483A2 (pt) * 2013-03-14 2017-07-18 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｅＩＦ２α経路の調節因子
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
KR20190015492A (ko) 2016-06-08 2019-02-13 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화학적 화합물
EP3468960B1 (en) 2016-06-08 2022-03-23 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2019008507A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited 2- (4-CHLOROPHENOXY) -N - ((1- (2- (4-CHLOROPHENOXY) ETHYNAZETIDIN-3-YL) METHYL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF ATF4 FOR THE TREATMENT OF CANCER AND D OTHER DISEASES
JP2020525513A (ja) 2017-07-03 2020-08-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物
CR20200054A (es) 2017-08-09 2020-03-21 Denali Therapeutics Inc Compuestos, composiciones y métodos
PL3676297T3 (pl) * 2017-09-01 2023-12-11 Denali Therapeutics Inc. Związki, kompozycje i sposoby
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
MX2020004519A (es) 2017-11-02 2020-11-09 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
CA3080959A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
CA3080808A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
BR112020008834A2 (pt) 2017-11-02 2020-12-22 Calico Life Sciences Llc Moduladores da via de estresse integrada
BR112020008836A2 (pt) 2017-11-02 2021-03-30 Calico Life Sciences Llc Moduladores da via de estresse integrada
JP7335241B2 (ja) 2017-11-02 2023-08-29 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
MX2020006115A (es) 2017-12-13 2020-11-09 Praxis Biotech LLC Inhibidores de la vía de respuesta al estrés integrada.
US20210130308A1 (en) 2018-03-23 2021-05-06 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors

Also Published As

Publication number Publication date
MX2021012904A (es) 2022-01-18
CA3137212A1 (en) 2020-10-29
AU2020262153A1 (en) 2021-11-11
CN114008041A (zh) 2022-02-01
WO2020216764A1 (en) 2020-10-29
SG11202111362SA (en) 2021-11-29
US20220213078A1 (en) 2022-07-07
BR112021020106A2 (pt) 2021-12-07
EP3959210A1 (en) 2022-03-02
JP2022530051A (ja) 2022-06-27
IL287378A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
PH12020551821A1 (en) Novel compounds
PH12021550310A1 (en) Novel sulfonamideurea compounds
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2021012903A (es) Moduladores de la via de respuesta integrada al estres.
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
PH12020500461A1 (en) 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-methylpropan-2-ol derivatives and related compounds as il-17 and ifn-gamma inhibitors for treating autoimmune diseases and chronic inflammation
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2022009243A (es) Moduladores de la via de respuesta integrada al estres.
MX2021007247A (es) Derivados de rapamicina.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2020008523A (es) Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).
PH12021550258A1 (en) Cdk8/19 inhibitors
EA202190339A1 (ru) Пиридопиримидины в качестве ингибиторов н4-гистаминовых рецепторов
MX2023004677A (es) Moduladores de la via de respuesta integrada al estres.